Moderna, Inc. (NASDAQ:MRNA) Given Average Rating of "Hold" by Brokerages

Moderna, Inc. (NASDAQ:MRNA - Get Free Report) has been assigned a consensus rating of "Hold" from the twenty-three research firms that are presently covering the firm, MarketBeat reports. Four analysts have rated the stock with a sell recommendation, fifteen have given a hold recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $46.61.

A number of equities research analysts have recently weighed in on MRNA shares. Evercore ISI reduced their price objective on shares of Moderna from $50.00 to $32.00 and set an "in-line" rating on the stock in a report on Friday, May 2nd. Citigroup began coverage on Moderna in a research note on Thursday, March 13th. They issued a "neutral" rating and a $40.00 price target on the stock. William Blair reaffirmed a "market perform" rating on shares of Moderna in a report on Monday, June 2nd. Morgan Stanley lowered their price objective on Moderna from $39.00 to $32.00 and set an "equal weight" rating for the company in a research report on Wednesday, April 9th. Finally, JPMorgan Chase & Co. cut their target price on Moderna from $33.00 to $26.00 and set an "underweight" rating on the stock in a research report on Thursday, May 22nd.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $27.59 on Tuesday. The company has a market cap of $10.67 billion, a price-to-earnings ratio of -3.16 and a beta of 1.86. The stock's 50-day moving average is $26.46 and its two-hundred day moving average is $31.63. Moderna has a 1-year low of $23.15 and a 1-year high of $129.39.

Moderna (NASDAQ:MRNA - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, topping analysts' consensus estimates of ($2.92) by $0.40. Moderna had a negative net margin of 105.67% and a negative return on equity of 28.69%. The firm had revenue of $108.00 million for the quarter, compared to analyst estimates of $130.35 million. During the same period in the prior year, the firm earned ($3.07) earnings per share. The business's quarterly revenue was down 35.3% compared to the same quarter last year. Equities research analysts anticipate that Moderna will post -9.61 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. New York Life Investment Management LLC lifted its holdings in shares of Moderna by 14.2% during the fourth quarter. New York Life Investment Management LLC now owns 53,017 shares of the company's stock worth $2,204,000 after purchasing an additional 6,609 shares during the period. Proficio Capital Partners LLC lifted its stake in shares of Moderna by 4,418.9% in the 4th quarter. Proficio Capital Partners LLC now owns 147,360 shares of the company's stock worth $6,127,000 after acquiring an additional 144,099 shares during the period. Parkside Financial Bank & Trust lifted its stake in shares of Moderna by 50.0% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,872 shares of the company's stock worth $78,000 after acquiring an additional 624 shares during the period. US Bancorp DE boosted its holdings in shares of Moderna by 13.2% in the fourth quarter. US Bancorp DE now owns 16,962 shares of the company's stock valued at $705,000 after acquiring an additional 1,981 shares in the last quarter. Finally, Metis Global Partners LLC increased its stake in shares of Moderna by 35.3% during the fourth quarter. Metis Global Partners LLC now owns 20,076 shares of the company's stock worth $835,000 after acquiring an additional 5,242 shares during the period. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.